RESEARCH



No gender-specific differences in comorbidities in patients with chronic obstructive pulmonary disease due to alpha-1 antitrypsin deficiency

Josef Yayan^{1*} and Kurt Rasche¹

Abstract

Background A deficiency in alpha-1 antitrypsin (A1AD) leads to increased activity of proteolytic enzymes. The consequence is a damage of airways and alveoli and, ultimately, the development of emphysema and chronic obstructive pulmonary disease (COPD).

Purpose Gender-specific differences in terms of comorbidities are still unclear due to the rarity of this genetic autosomal recessive disease.

Patients and methods This retrospective observational study was conducted from January 1, 2005, to November 30, 2022, in the Department of Pneumology, HELIOS University-Clinic Wuppertal, University of Witten/Herdecke, Germany.

Results Eleven patients with COPD due to A1AD could be included into the study (6 males, 54.5%; 95% *Cl* 23.4–83.3%) with a mean age of 53.9 ± 11.6 years. The male study participants were of normal weight body mass index 24.17 ± 4.67, while the females were obese 31.2 ± 4.87 (p = 0.054). More women were smokers (60%, p = 0.567). Furthermore, all of the women had panlobular emphysema (100%, p = 0.455). All subjects suffered from COPD, with most male subjects in severe advanced stages (50%, p = 0.545). No case of liver involvement was observed in this study.

Conclusion The findings of this study showed no statistically relevant gender-specific differences in comorbidities of patients with COPD due to A1AD.

Keywords Sex, Alpha-1 antitrypsin deficiency, Comorbidities, COPD, Emphysema

Background

The rare hereditary disease alpha-1 antitrypsin deficiency (A1AD) leads to destruction of the air sacs in the lungs [1]. However, rapid diagnosis, symptomatic therapy, and replacement of the missing enzyme can significantly slow

¹ Department of Internal Medicine, Division of Pulmonary, Allergy and Sleep Medicine, HELIOS Clinic Wuppertal, Witten/Herdecke University, Heusnerstr 40, 42283 Wuppertal, Germany the progression of the disease. Due to a genetic defect, the enzyme A1AT is incorrectly formed in the liver [2]. The altered protein cannot be released from the liver into the bloodstream, which can damage liver tissue. This also causes a deficiency of A1AT in the lungs [2], where the enzyme protects the lungs from self-digestion through protein-splitting enzymes that are released by the body's own defense cells to protect against bacteria. In the case of a large A1AD, the damage to the lungs includes attacks on the elastic tissue and destruction of particularly the alveoli [2]. The symptoms and consequences are similar to those of chronic obstructive pulmonary disease



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

^{*}Correspondence:

Josef Yayan

josef.yayan@hotmail.com

(COPD) caused by nicotine consumption, with which the disease is therefore often confused [3]. However, symptoms of A1AD typically appear at a younger age [4]. Moreover, in addition to pulmonary emphysema, bronchiectasis can also form [5].

Almost every person with COPD also has an accompanying disease affecting another organ system [6]. In the case of COPD, concomitant diseases of the heart and blood vessels, or risk factors to contract those diseases, are particularly common [7]. More than half of patients with COPD have vascular calcification or high blood pressure. Other common comorbidities include heart attacks, diabetes, and high cholesterol levels [8]. Additionally, over half of people with COPD have four or more comorbidities [6].

Different gender-specific conclusions have been postulated regarding the increased risk of men developing COPD due to confounding with the risk factor of smoking [9]. Some studies have suggested an increased risk for men due to greater occupational and environmental exposures [10-12].

Therefore, the aim of the present study was to obtain more comprehensive and precise information about the comorbidities of patients with COPD due to A1AD in a sex comparison. For this purpose, all necessary data were collected on patients with COPD due to A1AD as determined by the International Statistical Classification of Disease (ICD E88.0) by conducting a search of the HELIOS Clinic Wuppertal database at the Witten/Herdecke University in Germany.

Material and methods

Study design and setting

We examined all data relevant to this retrospective observational study that were collected after treatment from the clinical database in the Department of Pneumology of the HELIOS Clinic Wuppertal for the period January 1, 2005, to December 31, 2022.

The HELIOS University Clinic Wuppertal is the largest hospital in the Bergisches Land in the state of North Rhine–Westphalia in Germany. It has 1051 beds and three locations, as well as 26 specialist departments. Since 2004, it has been the first university hospital run by a private operator in Germany. The clinic takes in around 50,000 inpatients and carries out around 100,000 outpatient treatments every year. The Department of Pneumology at the HELIOS Clinic in Wuppertal treats all types of lung diseases.

Alpha-1 antitrypsin deficiency

Alpha-1-antitrypsin deficiency is an inherited condition caused by a gene mutation in which the lungs and liver are damaged by low levels of the enzyme A1AT. An A1AD can lead to coughing, sputum production, and shortness of breath—initially with exertion, but later, also at rest. These signs are similar to the symptoms of other common lung diseases, such as asthma or COPD [13].

To measure the levels of A1AT in blood serum, a sample of blood is collected in a test tube, and to determine of the type of A1AT damage, the doctor draws blood from a fingertip or earlobe. Measuring A1AT levels in the blood is more time-consuming. After collection, the blood sample is sent to an external laboratory. If the A1AT concentration is low, an A1AD may be present [14].

Another option is to use a rapid test on site in the doctor's office. This test enables A1AT to be ruled out quickly: After just 15 min, the doctor can find out, with a high degree of certainty, whether the patient has the greatest risk factor for A1AD, namely, the most common change in a particular allele—called the Z variant. It causes the protein A1AT to change and trigger an alpha-1 [15].

Chronic obstructive pulmonary disease (COPD)

COPD is a chronic, usually progressive, airway and lung disease characterized by airway obstruction that interferes with breathing and is not fully reversible after administration of bronchodilators. Diagnosis is by spirometry, and the forced expiratory volume in 1 s (FEV1) with COPD decreases annually as the disease progresses [16].

Pulmonary emphysema

Pulmonary emphysema is the chronic inflation of the lungs from air. This increases the volume of gas, making it difficult for the person affected by the disease to exhale. Typically, not all sections of the lung are involved [17].

Comorbidities

A concomitant disease is one that exists in a patient alongside an underlying disease that is the focus of therapy. It is also referred to as an additional diagnosis [18].

Statistical analysis

The mean values were calculated with the specification of the standard deviation for age, body mass index, pack years, length of hospital stay, and FEV1. These data were subjected to the independent-samples parametric *T*-test after checking for normality using the Kolmogorov– Smirnov test with Lilliefors correction. If the distribution of scores was not normal, the Mann–Whitney *U*-test was employed. Due to the small sample size of fewer than five observations, Fisher's exact test was used to calculate the association between the two dichotomous categorical variables comparing comorbidities between sexes. A *P*-value < 0.05 was considered statistically significant.

Results

A total of 11 patients with COPD due to A1AD (6 male, 54.5%; 95%CI 23.4-83.3%) were found in the records of the Department of Pneumology for the HELIOS Clinic Wuppertal at the University of Witten/Herdecke in Germany in the study period of January 1, 2005, to December 31, 2022. The mean age of the study participants was 53.9±11.6 years with no statistical differences between the two sexes (Table 1). There was no genderrelated difference in the mean time for diagnosis, mean age at diagnosis, or mean age at symptom onset for A1AD (Table 1). A family screening for A1AD was not conducted in these patients in this study (Table 1). The male study participants were of normal weight, while the females were obese, but the difference was without statistical relevance. The number of female smokers was higher in this study, also without statistical significance (Table 1). Antitrypsin phenotyping was not recorded in all patients. However, without any relevance for this study, the proteinase inhibitor (Pi) Pi^{ZZ} and Pi^{MZ} variants were common among the males (Table 1). In addition, all of the female participants with COPD exhibited the so-called panlobular emphysema (Table 1). All individuals in this study suffered from COPD, with most of the males in severe advanced stages of COPD, but without statistical significance (Table 1). Also without statistical significance, the male patients had more comorbidities, but there was no preponderance of one disease (Table 1). The female participants were prone to exacerbations of COPD. There was one death among the male study participants (Table 1).

Discussion

The results of this study showed no statistically relevant gender-specific differences in comorbidities in patients with COPD due to A1AD. A small number of the patients were found during the long follow-up period covered in this study. A1AD is a rare inherited disorder that has a major impact on quality of life and longevity in adults, especially in smokers [19]. A detailed analysis of this study found more smokers among the women, but onethird of the men were smokers. In smokers, A1AD leads to the development of emphysema. Because A1AT inhibits neutrophil elastase release, with a deficiency of A1AT, smoke-induced neutrophil elastase release is insufficiently inhibited. This leads to proteolytic damage to the pulmonary connective tissue, mainly from the elastic fibers, and the development of panlobular emphysema [20]. Therefore, patients with A1AD should stop smoking. All of the women in the present study had emphysema, compared to two-thirds of the men. Does gender really matter when it comes to this lung disease?

This disease was the first genetic risk factor described for COPD. More than 50 years since its description, new insights are still being provided into the more frequent occurrence of COPD in this rare disease. As already noted, the cause is a single genetic modification, and the clinical manifestations include emphysema, airway hyperreactivity, and bronchiectasis [20]. Indeed, the present study showed that all of the patients with A1AD developed COPD, with emphysema also often developing and fewer incidences of bronchiectasis. According to the results of other studies, patients with A1AD often have an increased risk of developing COPD and pulmonary emphysema [21, 22]. Deficiency of A1AT can progress to significant enzyme activity, which can lead to lung tissue disruption [21, 22]. The severity of COPD and emphysema can vary, typically manifesting in adulthood [21, 22]. Based on these findings, early diagnosis, regulated monitoring, and extensive treatment are definitely necessary in order to control the progression of this rare disease [21, 22].

The development of cirrhosis with A1AD is low [23], and no case of liver involvement was observed in this study, either. In addition, A1AD can cause liver disease according to former studies [24, 25]. The liver disease is ranging from mild liver enzyme abnormalities to more serious consequences such as liver cirrhosis [24, 25]. The liver complications can manifest in childhood or adulthood, which can lead to a different clinical presentation of A1AD [24, 25].

Developing these comorbidities is increased in homozygous genotypes in individuals with A1AD. Patients in another study frequently experienced emphysema, bronchiectasis, and bronchial thickening, as well as early onset respiratory symptoms [26]. The most common genotype was Pi^{ZZ}. Heterozygous genotypes and normal A1AD also showed significant lung disease [26]. Genetic counseling plays a critical role in understanding the diversity nature of A1AD [26]. Comprehensive treatment includes genetic testing for early detection, regular monitoring, and personalized treatment strategies [26]. Lifestyle changes, smoking cessation, and pulmonary rehabilitation are measures to improve the quality of life in this rare disease [26].

Many patients with advanced stages of COPD and emphysema have weight loss and a higher mortality rate. Many such patients were underweight in an earlier study [27]. However, underweight patients were not seen in this study. Instead, the male patients were of normal weight, and the women were overweight.

Some genetic variants of the proteinase inhibitor (Pi) A1AT have less serum concentration increases and are predisposed to liver disease and pulmonary emphysema. These deficiency variants can only be reliably diagnosed
 Table 1 Demographic data and comorbidities of patients with chronic obstructive pulmonary disease due to alpha-1 antitrypsin deficiency

n=6 (%)n=5 (%)Mean age: 5D454 ± 7.873.2 ± 1.480.80Mean age: stop (ange)244 - 0.9040 55 - 300.54Body mass index ± 5D3.12 ± 4.573.12 ± 4.570.54Mean age at signos eal phat -1 antityps in deficiency ± 5D3.32 ± 4.54.58 ± 1.770.178Mean age at signos eal phat -1 antityps in deficiency ± 5D3.32 ± 4.54.58 ± 1.770.178Mean age at signos eal phat -1 antityps in deficiency ± 5D3.32 ± 4.54.58 ± 1.770.18Mean age at signos eal phat -1 antityps in deficiency ± 5D3.32 ± 4.54.58 ± 1.770.58Family screening for al phat -1 antityps in deficiency ± 5D3.32 ± 4.53.84 ± 3.50.54 ± 1.550.58Sincker2.13.33.1600.5671.1601.10PMZ (1% of the stands of)1.16 + 1.1601.100.00.552Defining marker2.13.34.6070.00.12PMZ (1% of the stands of)2.13.34.6070.01.10PMZ (1% of the stands of)0.00.101.000.552Defining marker1.16.72.4401.100.01.10PMZ (1% of the stands of)2.15.31.6070.6001.10COPD GOLD II0.01.101.101.101.10COPD GOLD II0.16.71.6070.001.60COPD GOLD II0.16.71.6070.001.60COPD GOLD II0.16.71.6070.001.60COPD GOLD II0	Variable	Male n = 6 (%)	Female n = 5 (%)	<i>p</i> -value
Mean age 15D 545 ± 7.89 53.2 ± 14.8 0.89 Median age fangel 52.47 < -89 49.55 < -80 - Body mass index 5D 24.17 - 47.67 31.2 ± 4.82 0.54 Mean itter to dopase daha1 antityspin deficiency ± 5D 33.7 ± 4.5 45.8 ± 17.7 0.178 Mean age at diagnosis of alpha 1 antityspin deficiency ± 5D 33.7 ± 4.5 45.8 ± 17.7 0.178 Mean age at symptoms of alpha 1 antityspin deficiency ± 5D 33.7 ± 4.5 45.8 ± 17.7 0.178 Mean age at symptoms of alpha 1 antityspin deficiency ± 5D 33.7 ± 4.5 46.2 ± 1.2 ± 0.094 0.8 ± 5.7 Mean age at symptoms of alpha 1 antityspin deficiency ± 5D 33.7 ± 4.5 46.7 ± 1.2 ± 0.094 0.8 ± 5.7 Mean age at symptoms of alpha 1 antityspin deficiency ± 5D 33.7 ± 4.5 46.7 ± 1.2 ± 0.094 0.8 ± 5.7 Mean age at symptoms of alpha 1 antityspin deficiency ± 5D 2.1 ± 0.8 ± 0.2 ± 0.0				
Index age (ange)22.47-6942.4540Body mass index 4SD24.17.46731.24.4370.191Mean length of hopital sty in days66.67.270.56Mean length of hopital sty in days31.74.4545.81.17.00.178Mean age at dagnose alpha-1 anttrypsin deficiency in Sector30.34.6552.41.480.054Family scening for alpha-1 anttrypsin deficiency in Sector000Family scening for alpha-1 anttrypsin deficiency in Sector10.306.050.05Sinokar21.33.0016.070.011.01Family scening for alpha-1 anttrypsin deficiency in Sector21.33.0010.000.01Sinokar21.33.0010.000.010.010.01FSK 63% of the standard)21.03.0010.000.020.02FDV7 (5% of the standard)21.03.0010.000.020.02Unnown21.33.0010.000.020.02Deficiency in Sector3.6010.000.020.02COPD GOLD II21.0221.020.020.020.02COPD GOLD II21.0221.0210.000.020.02COPD GOLD II21.0221.0221.020.020.02COPD GOLD II21.0221.0221.0210.0210.02COPD GOLD II21.0221.0221.0210.0210.02COPD GOLD II21.0221.0221.0221.0210.02COPD GOLD II21.0221.0221.0221.02 <t< td=""><td>Mean age±SD</td><td>54.5±7.89</td><td>53.2±14.8</td><td>0.869</td></t<>	Mean age±SD	54.5±7.89	53.2±14.8	0.869
Bady magnitude2417446731.24.570.034Mean length of hosptal stay indys846.950.2170.258Mean age at sympose alpha 1 antryps in deficiency in year +51033.74.4545.81.17.00.178Mean age at sympose alpha 1 antryps in deficiency in year +52033.74.4552.44.14.80.054Family screening for alpha 1 antryps in deficiency in year +520000Smoker2 (33.3)6.07.120.0570.057Smoker10.67000.055PMS of the standard10.6700.0530.055PMS (3% of the standard)00.0330.0510.055PMS (3% of the standard)0.0610.000.0520.052PMS (0% of the standard)0.0610.000.0520.052PMS (0% of the standard)0.0610.000.0520.052PMS (0% of the standard)0.0610.000.0520.052PMS (0% of the standard)0.0610.000.000.052PMS (0% of the standard)0.0610.000.000.00PMS (0% of the standard)0.000.000.000.00PMS (0% of the standard)0.000.000.000.00PMS	Median age (range)	52 (47–69)	49 (35-80)	
Mean length of hospital stay in days84.6954.270.32Mean gen at dignone alpha-1 antitypisn deficiency in SD37.44.545.84.17.70.17.8Mean age at dignosis di alpha 1 antitypisn deficiency in SD33.14.545.84.17.70.17.8Mean age at dignosis di alpha 1 antitypisn deficiency in SD33.34.536.000.57.7Smoker2(33.3)36.000.57.7Smoker116.70.101.000.57.7Striftypisn hepotyping2(33.3)00.45.5PM2.(6% of the standard)0.01.000.45.5Unknown2(33.3)00.45.5Unknown perlysien0.01.000.42.5Unknown perlysien0.00.00.42.5Unknown perlysien1.00.70.00.42.5Unknown perlysien1.00.70.00.42.5Unknown perlysien1.00.70.00.42.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.55.5Unknown perlysien1.00.70.00.5.5Unknown perlysien1.00.70.00.5.5Unknown perlysien1.00.70.00.5.5Unknown perlysien1.00.7 <t< td=""><td>Body mass index \pm SD</td><td>24.17±4.67</td><td>31.2±4.87</td><td>0.054</td></t<>	Body mass index \pm SD	24.17±4.67	31.2±4.87	0.054
Mean aga at signose alpha-1 antitypsin deficiency s5D337 ±45458 ±1770.178Mean aga at signoses of alpha-1 antitypsin deficiency s5D337 ±4552 × 14 × 100108Family sciencing for alpha-1 antitypsin deficiency s5D0000Smoker2 (33.3)360,00.567000Mean gae at symptoms of alpha-1 antitypsin deficiency s02 (33.3)60,00.567000<	Mean length of hospital stay in days	8±6.9	5.6 ± 2.7	0.526
Mean age at diagnosis of alpha-1 antitrypsin deficiency ±5033 7± 4545 8± 17.70.178Mean age at symptoms of alpha-1 antitrypsin deficiency ±50000Smoker2 (33.3)3 (60)0.567Smoker2 (33.3)3 (60)0.567Multrypsin phenotyping1 (16.7)01.05PMZ (61% of the standard)01 (20)0.455Unknown2 (33.3)00.455Duffor of the standard)00.455Unknown2 (33.3)1000.455COPP GOLD000.0COPP GOLD1 (16.7)2 (40)0.455COPP GOLD1 (16.7)2 (40)0.455COPP GOLD1 (16.7)2 (40)0.455COPP GOLD IV3 (50)1 (20)0.455COPP GOLD IV3 (50)1 (20)0.57Corp Gold IV1 (67)01 (0Corp Gold IV1 (67)01 (0Corp Gold IV1 (67)01 (0Corp Gold IV1 (67)01 (0Corp Go	Mean time to diagnose alpha-1 antitrypsin deficiency in years \pm SD	33.7±4.5	45.8±17.7	0.178
Mean age at symptoms of alpha-1 antitypsin deficiency93465524 ± 1480054Family strening for alpha-1 antitypsin deficiency00577(Mean pack years)45 ± 53600578Antitypsin phonotyping1(167)01.0FM2 (5% of the standard)2(33.3)48000.455(Dist) FM2 (5% of the standard)2(33.3)48000.455(Dist) FM2 (5% of the standard)2(33.3)48000.455(Dist) FM2 (5% of the standard)2(33.3)2(40.0)0.455(Dist) FM2 (5% of the standard)1(6.7)2(40.0)0.455(Dist) FM2 (5% of the standard)2(33.3)2(40.0)0.455(Dist) FM2 (5% of the standard)2(33.0)1.000.545(Dist) FM2 (5% of the standard)2(33.0)1.000.545(Dist) FM2 (5% of the standard)1(6.7)1.000.545(Dist) FM2 (5% of the standard)1.001.000.545(Dist) FM2 (5% of the standard)1.001.000.555(Dist) FM2 (5% of the standard) <td>Mean age at diagnosis of alpha-1 antitrypsin deficiency ± SD</td> <td>33.7±4.5</td> <td>45.8±17.7</td> <td>0.178</td>	Mean age at diagnosis of alpha-1 antitrypsin deficiency ± SD	33.7±4.5	45.8±17.7	0.178
Family screening for alpha-1 antitrypsin deficiency00Smoler2 (33.3)3 (60)0.567(Mean pack years)45±545±12.50.589Antitrypsin phenoxyping11(67)01.0PSS (63% of the standard)2 (33.3)00.455PMZ (3W, 60 the standard)2 (33.3)00.455Unknown2 (33.3)00.455Dymonary emphysema01.000.655COPO GOLD I000.655COPO GOLD II1 (167)2 (40)0.545COPO GOLD III2 (33.3)2 (40)0.545COPO GOLD III1 (167)00.601COPO GOLD III1 (167)00.601COPO GOLD III1 (167)00.601COPO GOLD III1 (167)00.601Comolic sepiratory falue1 (167)00.601Chronic respiratory falue1 (167)00.601Chronic sepiratory falue1 (167)00.601Comolypertindis1 (167)00.601Comolypertindis1 (167)00.601Comolypertindis1 (167)00.601Comolypertindis1 (167)00.601Comolypertindis1 (167)00.601 </td <td>Mean age at symptoms of alpha-1 antitrypsin deficiency \pm SD</td> <td>39.3±6.5</td> <td>52.4±14.8</td> <td>0.054</td>	Mean age at symptoms of alpha-1 antitrypsin deficiency \pm SD	39.3±6.5	52.4±14.8	0.054
sincle2(33.3)3 (60)0.567(Mean pack years)45±545±50.89Antitypsin pheropying2(33.3)00.455PSS (63% of the standard)2(33.3)00.455Unknown2(33.3)4(80)0.242PZC (15% of the standard)2(33.3)4(80)0.242Dunnowy emphysema4(667,7)5(100)0.455COPD COLD II0000COPD COLD II2(33.3)2(40)0.545COPD COLD II3(50)1(20)0.545COPD COLD II3(50)1(20)0.545COPD COLD II3(50)1(20)0.545FEV1% mean ±SD322±15.6548±19.70.500Lung typeinflation01.01.0Ronchectasis11(6.7)01.0Puinonary fibrois11(6.7)01.0Conchectasis11(6.7)01.0Puinonary fibrois11(6.7)01.0Conchectasis11(6.7)01.0Puinonary fibrois11(6.7)01.0Conchectasis11(6.7)00.0Puinonary embolism11(6.7)00.0Puinonary embolism11(6.7)00.0Puinonary embolism11(6.7)00.0Puinonary embolism11(6.7)00.0Puinonary embolism11(6.7)00.0Puinonary embolism11(6.7)00.0Puinonary embolism11(6.7)	Family screening for alpha-1 antitrypsin deficiency	0	0	
(Mean pack years)45± 5046.7± 1.250989Antizysin phenotyping16.70000PSS (68% of the standard)2(33.3)00.2422Pulze (15% of the standard)2(33.3)4(80.0)0.2422Pulmonary emphysema2(33.3)4(80.0)0.2422COPD GOLD 1000.2422COPD GOLD 11(67.0)2(40.0)0.5452COPD GOLD 11(67.0)2(40.0)0.5452COPD GOLD 12(33.3)2(40.0)0.5452COPD GOLD 12(33.3)2(40.0)0.5452COPD GOLD 12(35.0)1(62.0)0.5452COPD GOLD 12(32.0)2(24.0)0.5452COPD GOLD 11(67.0)1(20.0)0.5452EV14 mean 5.0202.254.8± 19.70.5012Ling hyperinflation1(67.0)1(20.0)1.0Storact seles panes syndrome1(16.7)0.01.0Coronary fibrois1(67.0)10.01.0Coronary fibrois1(67.0)0.01.0Coronary embolism1(167.0)0.01.0Coronary embolism1(167.0)0.01.0Coronary embolism1(167.0)0.01.0Coronary embolism1(167.0)0.01.0Coronary embolism1(167.0)0.00.0Coronary embolism1(167.0)0.00.0Coronary embolism1(167.0)0.00.0Coronary embolism1(167.0)0.00.0Corona	Smoker	2 (33.3)	3 (60)	0.567
Antirypsin Phonotyping 1067 0 10 PK08 (68 difte standard) 2(33) 0 0 0 PK2 (16) the standard) 0 12(3) 0	(Mean pack years)	45 ± 5	46.7±12.5	0.898
PSS (63% of the standard)1 (167)01.0PMZ (15% of the standard)2 (33.3)00.455PDZ (15% of the standard)2 (33.3)4 (80.00.455Unknown2 (33.3)4 (80.00.455COPD GOLD I000.100.10COPD GOLD II1 (16.7)2 (40.00.545COPD GOLD II2 (33.3)2 (40.00.545COPD GOLD III2 (33.3)2 (40.00.545COPD GOLD III3 (50.0)1 (20.00.545EVIY & mean S.D3 (20.0)1 (16.7)1 (20.0)0.545EVIY & mean S.D1 (16.7)1 (20.0)0.101 (16.7)Shonchiectasis1 (16.7)1 (20.0)1 (10.0)1 (10.0)Pulmonary fibrosis1 (16.7)01 (10.0)1 (10.0)Chronic respiratory failure1 (16.7)01 (10.0)1 (10.0)Chronic respiratory failure1 (16.7)01 (10.0)1 (10.0)Pheumonia1 (16.7)01 (10.0)1 (10.0)1 (10.0)Pheumonia1 (16.7)000.055Heart failure1 (16.7)000.055Heart failure1 (16.7)000.055Heart failure1 (16.7)000.055Heart failure1 (16.7)000.055Heart failure1 (16.7)000.055Heart failure1 (16.7)000.055 <trr<tr>Heart failure1 (16.7)</trr<tr>	Antitrypsin phenotyping			
PMZ (61% of the standard)2 (33.3)00.453PZZ (15% of the standard)01 (20)0.453PURA (61% of the standard)2 (33.0)4 (80)0.453Quinnony emphysema4 (66.7)S (100)0.453COPD GOLD I0000COPD GOLD II2 (30.0)2 (40)0.543COPD GOLD III2 (30.0)1 (16.7)2 (40)0.545COPD GOLD IV3 (50.0)1 (20.0)0.545COPD GOLD IV2 (32.1)1 (20.0)0.545EVI Winnan (50.0)1 (16.7)0 (20.0)0.545PUImonary fibrois1 (16.7)0 (20.0)1 (20.0)Outprintation1 (16.7)0 (20.0)1 (20.0)Pulmonary fibrois1 (16.7)0 (20.0)1 (20.0)Corp corp corp corp corp corp corp corp c	PiSS (63% of the standard)	1 (16.7)	0	1.0
PZZ (19% of the standard)01 (20)0,453Unknown2(33.3)4 (80,0)0.453Pulmonay emphysema4 (60,7)5 (100)0.453COPD GOLD I1 (16,7)2 (40,0)0.545COPD GOLD II3 (30,0)1 (20,0)0.545COPD GOLD IV3 (20,0)1 (20,0)0.545FEV1% mean ±SD28.2 ± 15.654.8 ± 19.70.501Ling hyperinflation1 (16,7)00.545Asthma1 (16,7)00.545Ronchiectasis1 (16,7)00.547Pulmonay fibrosis1 (16,7)00.547Costructive sleep apnea syndrome1 (16,7)0.1011.01Exacerbation COPD2 (33,3)3 (60,0)1.02Costructive sleep apnea syndrome1 (16,7)0.1011.01Pulmonay embolism1 (16,7)00.101Rouchitish1 (16,7)00.1011.01Pulmonay embolism1 (16,7)0.1011.01Pulmonay embolism1 (16,7)0.1010.101Poptersoin1 (16,7)0.1010.101Poptersoin1 (16,7)0.1011.01Poptersoin1 (16,7)0.1010.101Poptersoin1 (16,7)0.1011.01Poptersoin1 (16,7)0.1010.101Poptersoin1 (16,7)0.1011.01Poptersoin1 (16,7)0.1010.101Poptersoin1 (16,7)0.1011.01Poptersoin<	PiMZ (61% of the standard)	2 (33.3)	0	0.455
Liknown2(33.3)4(80)0.242Pulmonay emphysema4(67)5(100)0451COPD GOLD11(67)2(40)0.545COPD GOLD112(33.3)2(40)0.545COPD GOLD112(33.3)2(40)0.545COPD GOLD112(33.3)2(40)0.545COPD GOLD112(33.3)2(40)0.545COPD GOLD112(32.15.6)36.81.19.700.501Lung hyserinflation1(16.7)1(20)10Pulmonay fibrois1(16.7)010Pulmonay fibrois1(16.7)010Chronic respiratory failure1(16.7)1010Pulmonay fibrois1(16.7)10010Pulmonay fibrois1(16.7)010Pulmonay fibrois1(16.7)010Pulmonay fibrois1(16.7)010Pulmonay emphysema1(16.7)010Pulmonay emphysema1(16.7)010Pulmonay fibrois1(16.7)010Pulmonay emphysema1(16.7)010Pulmonay emphysema1(16.7)10010Pulmonay fibrois1(16.7)10010Pulmonay fibrois1(16.7)010Pulmonay fibrois1(16.7)10010Pulmonay fibrois1(16.7)10010Pulmonay fibrois1(16.7)10010Pulmonay fibrois1(16.7)10010Pulmonay fibrois1(16.7)100	PiZZ (15% of the standard)	0	1 (20)	0.455
Pulmonary emphysema4(667,5(100)0,453COPD GOLD II0010COPD GOLD III1(16.7)2(40)0.543COPD GOLD III3(50)1(20)0.543COPD GOLD V3(50)1(20)0.543CPD GOLD N28.2±15.654.8±19.70.501Lung hyperinflation1(16.7)1(20)0.543Striman1(16.7)1(20)1.0Pulmonary fibrois1(16.7)01.0Chronic respiratory failure1(16.7)1(20)1.0Obstructive sleep apnea syndrome2(33.3)1(20)1.0Pulmonary embdism1(16.7)01.01.0Pulmonary embdism1(16.7)01.01.0Pulmonary embdism1(16.7)01.01.0Pulmonary embdism1(16.7)01.01.0Pulmonary embdism1(16.7)00.01.0Coronary heart disease2(33.3)1(20)0.41.0Pulmonary embdism1(16.7)1(20)0.41.0Coronary heart disease1(16.7)1(20)0.01.0Diabeter onephropathy1(16.7)1(20)1.01.0Diabeter onephropathy1(16.7)01.01.0Coronary heart disease1(16.7)01.01.0Diabeter onephropathy1(16.7)01.01.0Diabeter onephropathy1(16.7)01.01.0Chronic respiratedial disease1	Unknown	2 (33.3)	4 (80)	0.242
COPD GOLDII<	Pulmonary emphysema	4 (66.7)	5 (100)	0.455
COPD GOLD II1(16.7)2(40)0.543COPD GOLD IV2(33)2(40)1.0COPD GOLD IV3(50)1(20)0.545EV1% mean ±SD282 ± 1.5.6548 ± 19.70.505Lung hyperinflation01(20)0.455Asthma1(16.7)1(20)1.0Bronchectasis1(16.7)01.0Pulmonary fibrosis1(16.7)01.0Chronic respiratory failure1(16.7)01.0Obstructive sleep apnea syndrome2(33.3)3(60)0.567Long oxygen therapy2(33.3)3(60)1.0Pourmonia1(16.7)01.01.0Ronchitis1(16.7)01.01.0Pourmonia1(16.7)01.01.0Coronary heard fisses1(16.7)01.01.0Putinary etilases1(16.7)01.01.0Left restricular dysfunction1(16.7)1.00.4551.0Pripheral atterial disease1(16.7)1.01.01.0Diabetic nephropathy1(16.7)1.01.01.0Diabetic nephropathy1(16.7)01.01.0Lipstruct infection1(16.7)01.01.0Alberd inferion1(16.7)01.01.0Diabetic nephropathy1(16.7)01.01.0Lipstruct infection1(16.7)01.01.0Alberd inferion1(16.7)01.01.0<	COPD GOLD I	0	0	1.0
COPD GOLD III2 (40)1.0COPD GOLD V3(50)1.20)0.545FKV mean ± SD28.2 ± 15.648.8 ± 19.70.050Lung hyperinflation01.200.455Asthma1.06.71.000.051Bronchiectasis1.06.701.0Pulmoary fibrosis1.06.701.0Chornic respiratory failure1.06.71.201.0Distructive sleep apnea syndrome1.06.71.201.0Exacerbation COPD2.33.33.6000.567Long oxygen therapy2.03.33.6001.0Pulmonary embolism1.06.701.0Pulmonary embolism1.06.701.0Coronary heart disease00.01.0Pulmonary embolism1.06.700.01.0Coronary heart disease1.06.700.01.0Preipheral arterial disease1.06.70.00.55Lipotophythy1.06.70.00.551.0Diabetes1.06.70.00.01.0Diabeter coloring trifterion1.06.70.00.01.0Uninary trait divertion01.00.01.0Diabeter coloring trifterion1.06.70.00.01.0Diabeter coloring trifterion1.06.70.00.01.0Uninary trait infection1.06.70.00.01.0Altoring trifterion1.06.70.00.01.0Diabeter	COPD GOLD II	1 (16.7)	2 (40)	0.545
COPD GOLD V1 (20)0.543FEV1% mean ± SD28.2± 15.654.8± 19.70.050Lung hyperinflation01.200.455Astma1 (16.7)1.201.0Bronchiectasis1 (16.7)01.0Pulmonary fibrosis1 (16.7)01.0Obstructive sleep apnea syndrome1 (16.7)01.0Exacerbation COPD2 (33.3)3 (60)0.567Long oxygen therapy2 (33.3)1 (20)1.0Pulmonary fibrosis1 (16.7)01.0Postmention1 (16.7)01.0Preumonia1 (16.7)01.0Preumonia1 (16.7)01.0Pulmonary embolism1 (16.7)01.0Atrial formitation1 (16.7)01.0Pulmonary embolism1 (16.7)00.575Left ventructar dysfunction1 (16.7)00.555Left ventructar dysfunction1 (16.7)00.555Left ventructar dysfunction1 (16.7)00.555Left ventructar dysfunction1 (16.7)00.0Diabetes1 (16.7)01.01.0Diabetes replenopativ1 (16.7)00.01.0Liportopativ1 (16.7)00.01.0Liportopativ1 (16.7)00.01.0Liportopativ1 (16.7)00.01.0Liportopativ1 (16.7)00.01.0Liportopativ <td>COPD GOLD III</td> <td>2 (33.3)</td> <td>2 (40)</td> <td>1.0</td>	COPD GOLD III	2 (33.3)	2 (40)	1.0
FEV <table-cell><table-cell><table-row><math>FEV<table-row><table-cell></table-cell></table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></table-row></math></table-row></table-cell></table-cell>	COPD GOLD IV	3 (50)	1 (20)	0.545
Lung hyperinflation01(20)0.455Astma1(16.7)1(20)1.0Bronchicetasis1(16.7)01.0Pulmonary fibrosis1(16.7)000Obstructive sleep apnea syndrome1(16.7)1(20)1.0Exacerbation COPD2(33.3)3(60)0.567Long oxygen therapy2(33.3)1(20)1.0Pneumonia1(16.7)01.0Bronchitis1(16.7)01.0Pulmonary embolism1(16.7)01.0Pulmonary embolism1(16.7)01.0Coronary heart disease2(33.3)00.575Heart failure01.01.0Porpheral arterial disease1(16.7)00.455Idef ventricular dysfunction1(16.7)1.00.455Phypertension1(16.7)1.00.455Idephotaphy1(16.7)01.01.0Ibabetes1(16.7)1.01.01.0Ibabetes1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia1(16.7)01.01.0Ibapetentinia<	FEV1% mean±SD	28.2±15.6	54.8±19.7	0.050
Arma 1 (16.7) 1 (20) 1.0 Bronchiectasis 1 (16.7) 0 1.0 Pulmonary fibrosis 1 (16.7) 0 1.0 Chronic respiratory failure 1 (16.7) 0 1.0 Obstructive sleep apnea syndrome 1 (16.7) 1 (20) 1.0 Exacerbation COPD 2 (33.3) 1 (20) 1.0 Long oxygen therapy 2 (33.3) 1 (20) 1.0 Polemonia 1 (16.7) 0 1.0 Bronchitis 1 (16.7) 0 1.0 Pulmonary embolism 1 (16.7) 0 1.0 Atrial fibrillation 1 (16.7) 0 1.0 Coronary heard isease 2 (33.3) 0 0.455 Left ventricular dysfunction 0 1.0 1.0 Preipheral atterial disease 1 (16.7) 0 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hyporcholesterolemia 0 <t< td=""><td>Lung hyperinflation</td><td>0</td><td>1 (20)</td><td>0.455</td></t<>	Lung hyperinflation	0	1 (20)	0.455
Bronchiectasis1 (16.7)01.0Pulmonary fibrosis1 (16.7)01.0Chronic respiratory failure1 (16.7)01.0Obstructive sleep apnea syndrome1 (16.7)1 (20)1.0Exacerbation COPD2 (33.3)3 (60)56.7Long oxygen therapy2 (33.3)1 (20)1.0Pueumonia1 (16.7)01.0Bronchitis1 (16.7)01.0Pulmonary embolism1 (16.7)01.0Atrial fibrillation1 (16.7)00.455Coronary heart disease2 (33.3)00.4555Left ventricular dysfunction01.00.4555Hypertension1 (16.7)0.01.0Diabetic nephropathy1 (16.7)0.01.0Diabetic nephropathy1 (16.7)0.00.455Hyponatremia1 (16.7)0.01.0Diabetic nephropathy1 (16.7)0.00.455Hyponatremia1 (16.7)0.01.0Urinary tract infection1 (16.7)0.00.455Hyponatremia1 (16.7)0.01.0Urinary tract infection1 (16.7)0.01.0Alcoholism1 (16.7)0.01.0Aleray1 (16.7)0.01.0Diabetic nephropathy1 (16.7)0.01.0Urinary tract infection1 (16.7)0.01.0Aleray1 (16.7)0.01.0Diabetic nephropathy1 (16.7)<	Asthma	1 (16.7)	1 (20)	1.0
Pulmonary fibrosis1 (167,01.0Chronic respiratory failure1 (167,1 (20)1.0Obstructive sleep apnea syndrome1 (167,3 (60)0.567Exacerbation COPD2 (33.3)1 (20)1.0Long oxygen therapy2 (33.3)1 (20)1.0Pneumonia1 (16.7)01.0Bronchitis1 (16.7)01.0Pulmonary embolism1 (16.7)01.0Atrial fibrillation1 (16.7)00.455Left vertricular dysfunction01.01.0Prephenarial disease1 (16.7)1.00.455Left vertricular dysfunction1 (16.7)01.0Diabetes1 (16.7)01.01.0Diabetes1 (16.7)01.01.0Diabetes1 (16.7)01.01.0Diabetes1 (16.7)01.01.0Hypernolestrolemia1 (16.7)01.01.0Urinary tract infection1 (16.7)01.01.0Alfer stroke1 (16.	Bronchiectasis	1 (16.7)	0	1.0
Chronic respiratory failure 1 (16.7) 0 1.0 Obstructive sleep apnea syndrome 1 (16.7) 1 (20) 1.0 Exacerbation COPD 2 (33.3) 3 (60) 0.567 Long oxygen therapy 2 (33.3) 1 (20) 1.0 Pneumonia 1 (16.7) 0 1.0 Bronchitis 1 (16.7) 0 1.0 Pulmonary embolism 1 (16.7) 0 1.0 Atrial fibrillation 1 (16.7) 0 1.0 Coronary heart disease 2 (33.3) 0 0.4555 Heart failure 0 1.0 1.0 Coronary heart disease 1 (16.7) 0 0.4555 Hyperchension 1 (16.7) 1.0 0.4555 Usibabetic nephropathy 1 (16.7) 1.0 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hypercholesterolemia 1 (16.7) 0 1.0 Urinary ttact infection 1 (16.	Pulmonary fibrosis	1 (16.7)	0	1.0
Obstructive sleep apnea syndrome 1 <	Chronic respiratory failure	1 (16.7)	0	1.0
Exacerbation COP 2 (33.3) 3 (60) 0.567 Long oxygen therapy 2 (33.3) 1 (20) 1.0 Pneumonia 1 (16.7) 0 1.0 Bronchitis 1 (16.7) 0 1.0 Pulmonary embolism 1 (16.7) 0 1.0 Atrial fibrillation 1 (16.7) 0 1.0 Coronary heart disease 2 (33.3) 0 0.455 Heart failure 0 1 (20) 0.455 Left ventricular dysfunction 0 1 (20) 0.455 Hypertension 1 (16.7) 1 (20) 1.0 Diabetes 1 (16.7) 1 (20) 1.0 Diabetes 1 (16.7) 0 1.0 Diabetes 1 (16.7) 0 1.0 Hypencholesterolemia 1 (16.7) 0 1.0 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0	Obstructive sleep apnea syndrome	1 (16.7)	1 (20)	1.0
Long oxygen therapy2(33)1(20)1,0Pneumonia1(167)01,0Bronchitis1(167)01,0Pulmonary embolism1(167)01,0Atrial fibrillation1(16,7)00,455Coronary heart disease2(33,3)00,455Heart failure01(20)0,455Left ventricular dysfunction01(20)0,455Hypertension1(16,7)00,455Diabetes1(16,7)01,0Diabetes1(16,7)01,0Diabetes1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,455Hyportonian1(16,7)00,016Alterstoke1(16,7)00,016Alterstoke1(16,7)00,016Diabete1(16,7)00,016Diabete1(16,7)00,016Diabete1(16,7)00,016Diabete1(16,7)00,016Diabete1(16,7)00,016Diabete1(16,7)00,016Diabete1(16,7) <t< td=""><td>Exacerbation COPD</td><td>2 (33.3)</td><td>3 (60)</td><td>0.567</td></t<>	Exacerbation COPD	2 (33.3)	3 (60)	0.567
Preumonia 1 (16.7) 0 1.0 Bronchitis 1 (16.7) 0 1.0 Pulmonary embolism 1 (16.7) 0 1.0 Atrial fibrillation 1 (16.7) 0 1.0 Coronary heart disease 2 (33.3) 0 0.455 Heart failure 0 1 (20) 0.455 Left ventricular dysfunction 0 1 (20) 0.455 Hypertension 1 (16.7) 1 (20) 0.455 Diabets 1 (16.7) 1 (20) 0.455 Diabets 1 (16.7) 1 (20) 1.0 Diabets 1 (16.7) 0 1.0 Diabets 1 (16.7) 0 1.0 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0	Long oxygen therapy	2 (33.3)	1 (20)	1.0
Bonchitis I I I I Pulmonary embolism 1(16.7) 0 1.0 Atrial fibrillation 1(16.7) 0 0.455 Coronary heart disease 2(33.3) 0 0.455 Heart failure 0 1(20) 0.455 Left ventricular dysfunction 0 1(20) 0.455 Hypertension 1(16.7) 1(20) 0.455 Diabetes 1(16.7) 1(20) 0.455 Diabetes 1(16.7) 1(20) 1.0 Diabetes 1(16.7) 0 1.0 Diabeter nephropathy 1(16.7) 0 1.0 Hyponatremia 1(16.7) 0 0.455 Hyponatremia 1(16.7) 0 1.0 Urinary tract infection 1(16.7) 0 1.0 Alcoholism 1(16.7) 0 1.0 Alterytoke 1(16.7) 0 1.0 Alterytoke 1(16.7) 0 1.0	Pneumonia	1 (16.7)	0	1.0
Pulmonary embolism 1.0 0 1.0 Atrial fibrillation 1(16.7) 0 1.0 Coronary heart disease 2(33.3) 0 0.455 Heart failure 0 1(20) 0.455 Left ventricular dysfunction 0 1(20) 0.455 Hypertension 1(20) 0.455 0.455 Pripheral arterial disease 1(16.7) 1(20) 0.455 Diabetes 1(16.7) 0 1.0 Diabetes 1(16.7) 0 1.0 Hyponatremia 1(16.7) 0 1.0 Hyponatremia 1(16.7) 0 1.0 Hyponatremia 1(16.7) 0 1.0 Hyponatremia 1(16.7) 0 1.0 Urinary tract infection 1(16.7) 0 1.0 Alcoholism 1(16.7) 0 1.0 Alcoholism 1(16.7) 0 1.0 Alter stroke 1(16.7) 0 1.0 Allergy <td< td=""><td>Bronchitis</td><td>1 (16.7)</td><td>0</td><td>1.0</td></td<>	Bronchitis	1 (16.7)	0	1.0
Atrial fibilitation 1 (6.7) 0 1.0 Coronary heart disease 2 (33.3) 0 0.455 Heart failure 0 1 (20) 0.455 Left ventricular dysfunction 0 1 (20) 0.455 Hypertension 1 (16.7) 1 (20) 0.455 Peripheral arterial disease 1 (16.7) 1 (20) 0.10 Diabetes 1 (16.7) 0 1.0 Diabetes onephropathy 1 (16.7) 0 1.0 Hyponatremia 0 1 (20) 0.455 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Diabete 1 (16.7) 0 1.0	Pulmonary embolism	1 (16.7)	0	1.0
Coronary heart disease 2 (33.3) 0 0.455 Heart failure 0 1 (20) 0.455 Left ventricular dysfunction 0 1 (20) 0.455 Hypertension 1 (16.7) 1 (20) 1.0 Peripheral arterial disease 1 (16.7) 0 1.0 Diabetes 1 (16.7) 0 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 0 1.0 1.0 Alcoholism 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0	Atrial fibrillation	1 (16.7)	0	1.0
Heart failure111100.455Left ventricular dysfunction0100.455Hypertension1111.01.0Peripheral arterial disease111.01.01.0Diabetes1111.01.01.0Diabetic nephropathy111.01.01.0Hypercholesterolemia011.00.455Hyponatremia011.01.0Urinary tract infection11.01.01.0Alcoholism11.16.701.0Alter stroke11.16.701.0Allergy11.16.701.0Death11.16.701.0	Coronary heart disease	2 (33.3)	0	0.455
Left ventricular dysfunction 0 1 (20) 0.455 Hypertension 1 (16.7) 1 (20) 1.0 Peripheral arterial disease 1 (16.7) 0 1.0 Diabetes 1 (16.7) 1 (20) 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hypercholesterolemia 0 1 (20) 0.455 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 0 1.0 1.0 Alcoholism 1 (16.7) 0 1.0 Alter stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Heart failure	0	1 (20)	0.455
Hypertension 1 (16.7) 1 (20) 1.0 Peripheral arterial disease 1 (16.7) 0 1.0 Diabetes 1 (16.7) 1 (20) 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hypercholesterolemia 0 1 (20) 0.455 Hyponatremia 0 1 (20) 0.455 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alter stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Left ventricular dysfunction	0	1 (20)	0.455
Peripheral arterial disease 1 (16.7) 0 1.0 Diabetes 1 (16.7) 1 (20) 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hypercholesterolemia 0 1 (20) 0.455 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alter stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Hypertension	1 (16.7)	1 (20)	1.0
Diabetes 1 (16.7) 1 (20) 1.0 Diabetic nephropathy 1 (16.7) 0 1.0 Hypercholesterolemia 0 1 (20) 0.455 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alter stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Peripheral arterial disease	1 (16.7)	0	1.0
Diabetic nephropathy 1 (16.7) 0 1.0 Hypercholesterolemia 0 1 (20) 0.455 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 After stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Diabetes	1 (16.7)	1 (20)	1.0
Hypercholesterolemia 0 1 (20) 0.455 Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alter stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Diabetic nephropathy	1 (16.7)	0	1.0
Hyponatremia 1 (16.7) 0 1.0 Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 Alter stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Hypercholesterolemia	0	1 (20)	0.455
Urinary tract infection 1 (16.7) 0 1.0 Alcoholism 1 (16.7) 0 1.0 After stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Hyponatremia	1 (16.7)	0	1.0
Alcoholism 1 (16.7) 0 1.0 After stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Urinary tract infection	1 (16.7)	0	1.0
After stroke 1 (16.7) 0 1.0 Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	Alcoholism	1 (16.7)	0	1.0
Allergy 1 (16.7) 0 1.0 Death 1 (16.7) 0 1.0	After stroke	1 (16.7)	0	1.0
Death 1 (16.7) 0 1.0	Allergy	1 (16.7)	0	1.0
	Death	1 (16.7)	0	1.0

Abbreviations: COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, Pi proteinase inhibitor, SD standard deviation

by phenotyping. While many genetic variants of A1AD are known, only a few are associated with a clinically relevant deficiency. The most common type of defect is the homozygous Z phenotype (Pi^{ZZ}) [28].

The Pi^{MZ} phenotype of A1AT deficiency has emerged as key for in vivo studies of liver response, because synthesis and blocking of secretion occur simultaneously. In this study, as well, the Pi^{MZ} phenotype occurred frequently. However, phenotyping was not carried out in all patients, who had come to the hospital not only for clarification of this rare disease but also for other health reasons.

Patients with A1AD have been reported to have a higher prevalence of arterial hypertension, chronic kidney disease, and diabetes. They also have been shown to have more consultations and more frequent and longer hospital stays [29]. While we also observed the comorbidities in this study, a long hospital stay was not seen.

One study found that patients with A1AD have lower systolic and diastolic blood pressure, lower plasma triglycerides and residual cholesterol, a reduced risk of myocardial infarction, and a reduced risk of coronary artery disease [30]. These diseases were also under-represented in the present study.

Study limitations

Only a small number of patients with COPD due to A1AD could be found for analysis in this study because it was a single-center study. The information on comorbidities was based on the record in the files of the study site clinic. The small number of patients made the comparison of comorbidities based on sex more difficult. Genotyping data were only available for a minority of patients. Nonetheless, a correct segregation of individuals with severe A1AD probably occurred.

The normality tests compare the values in the sample to a normally distributed set of values with the same mean and standard deviation; the null hypothesis is that the sampling distribution is normal. For small sample sizes, there is little power to reject the null hypothesis, and thus, small samples are most likely to normality tests [31]. With large samples, even a small deviation from normality would produce significant results, although this small deviation does not affect the results of a parametric test.

Conclusions

This study showed no significant gender-specific differences in terms of comorbidities present with the very rare hereditary disorder A1AD.

Acknowledgements None

Authors' contributions

YJ made significant contributions to the reported work, be it in conception, study design, conduct, data collection, analysis, writing, and interpretation. RK revised and critically reviewed the article.

Funding

None.

Availability of data and materials

The authors confirm that all data generated or analyzed during this study are included in this article.

Declarations

Ethics approval and consent to participate

The Ethics Committee of Witten/Herdecke University in Witten, Germany, approved this study. The legal basis for processing of the relevant personal data was obtained from each study participant after they provided voluntary written consent, in accordance with the European General Data Protection Regulation. All personal data from all study participants was removed prior to data processing.

Consent for publication

We confirm that all materials included in this manuscript can be published.

Competing interests

The authors declare that they have no competing interests.

Received: 4 August 2023 Accepted: 24 November 2023 Published online: 29 November 2023

References

- Udhaya Kumar S, Madhana Priya N, Thirumal Kumar D et al (2021) An integrative analysis to distinguish between emphysema (EML) and alpha-1 antitrypsin deficiency-related emphysema (ADL)—a systems biology approach. In: Donev R, Karabencheva-Christova T (eds) Advances in protein chemistry and structural biology, vol 127. Academic Press, Cambridge, MA, pp 315-342
- 2. Hazari YM, Bashir A, Habib M et al (2017) Alpha-1-antitrypsin deficiency: genetic variations, clinical manifestations and therapeutic interventions. Mutat Res Rev Mutat Res 773:14-25
- McElvaney OJ, Cleary B, Fraughen DD et al (2022) Attitudes towards 3. vaccination for coronavirus disease 2019 in patients with severe alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis 9(2):266-273
- 4. McElvaney NG, Stoller JK, Buist AS et al (1997) The a1-Antitrypsin Deficiency Registry Study Group. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of α 1-antitrypsin deficiency. Chest. 111(2):394-403
- 5. Huang YT, Wencker M, Driehuys B (2021) Imaging in alpha-1 antitrypsin deficiency: a window into the disease. Ther Adv Chronic Dis. 12 suppl:20406223211024524
- Kim-Dorner SJ, Schmidt T, Kuhlmann A, Graf von der Schulenburg JM, 6. Welte T, Lingner H (2022) Age- and gender-based comorbidity categories in general practitioner and pulmonology patients with COPD. NPJ Prim Care Respir Med 32(1):17
- 7 Yin HL, Yin SQ, Lin QY, Xu Y, Xu HW, Liu T (2017) Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine 96(19):e6836
- 8. Cavaillès A, Brinchault-Rabin G, Dixmier A et al (2013) Comorbidities of COPD. Eur Respir Rev 22(130):454-475
- Aryal S, Diaz-Guzman E, Mannino DM (2013) COPD and gender differ-9. ences: an update. Transl Res 162(4):208-218
- 10. Grahn K, Gustavsson P, Andersson T et al (2021) Occupational exposure to particles and increased risk of developing chronic obstructive pulmonary disease (COPD): a population-based cohort study in Stockholm. Sweden Environ Res 200:111739

- Hart JE, Laden F, Eisen EA, Smith TJ, Garshick E (2009) Chronic obstructive pulmonary disease mortality in railroad workers. Occup Environ Med 66(4):221–226
- Bergdahl IA, Torén K, Eriksson K, Hedlund U, Nilsson T, Flodin R, Järvholm (2004) Increased mortality in COPD among construction workers exposed to inorganic dust. Eur Respir J. 23(3):402–406
- 13. Kelly E, Greene CM, Carroll TP, McElvaney NG, O'Neill SJ (2010) Alpha-1 antitrypsin deficiency. Respir Med 104(6):763–772
- Gökhan P, Sema A (2018) Evaluation of alpha-1-antitrypsin levels in blood serum of patients with chronic obstructive pulmonary disease. Acta Biomed 90(1):37–43
- Jardim JR, Casas-Maldonado F, Fernandes FLA, Castellano MVCO, Torres-Durán M, Miravitlles M (2021) Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. J Bras Pneumol 47(3):e20200380
- Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L (2007) Definition, epidemiology and natural history of COPD. Eur Respir J 30(5):993–1013
- 17. Thurlbeck WM, Müller NL (1994) Emphysema: definition, imaging, and quantification. Am J Roentgenol 163(5):1017–1025
- Moffat K, Mercer SW (2015) Challenges of managing people with multimorbidity in today's healthcare systems. BMC Fam Pract 16:129
- de Vos JD, Hillberg O, Perch M, Jensen JU, Wilcke JT, Løkke A (2021) Alpha-1-antitrypsin deficiency. Ugeskr Laeger. 183(30):V02210150. Danish
- Abboud RT, Ford GT, Chapman KR (2005) Emphysema in α1-antitrypsin deficiency: does replacement therapy affect outcome? Treat Respir Med 4(1):1–8
- Sandhaus R, Strange C, Stone G et al (2020) Comorbidity associations with AATD among commercially insured and Medicare beneficiaries with COPD in the US. Int J Chron Obstruct Pulmon Dis 15:2389–2397. https:// doi.org/10.2147/COPD.S263297. PMID:33116454; PMCID: PMC7547287
- Wells AD, Woods A, Hilleman DE, Malesker MA (2019) Alpha-1 antitrypsin replacement in patients with COPD. PT. 44(7):412–415. PMID: 31258312; PMCID: PMC6590928
- 23 Cosme A, Ojeda E, Torrado J, Carrera A, Castiella A, Zapata E (2003) Alteraciones hepáticas por déficit de alfa-1-antitripsina en adultos. Estudio de 5 pacientes y análisis de los casos publicados en la bibliografía española [Liver alterations due to alpha-1-antitrypsin deficiency in adults. Study of 5 patients and analysis of the cases reported in the Spanish literature]. Gastroenterol Hepatol. 26(4):251-256. Spanish
- Mitchell EL, Khan Z (2017) Liver disease in alpha-1 antitrypsin deficiency: current approaches and future directions. Curr Pathobiol Rep. 5(3):243–252. https://doi.org/10.1007/s40139-017-0147-5. Epub 2017 Jul 10. Erratum in: Curr Pathobiol Rep. 2018;6(1):97. PMID: 29399420; PMCID: PMC5780543
- Patel D, McAllister SL, Teckman JH (2021) Alpha-1 antitrypsin deficiency liver disease. Transl Gastroenterol Hepatol 6:23. https://doi.org/10.21037/ tgh.2020.02.23. PMID: 33824927; PMCID: PMC7829072
- Felisbino MB, Fernandes FLA, Nucci MCNM et al (2018) The patient profile of individuals with alpha-1 antitrypsine gene mutations at a referral center in Brazil. J Bras Pneumol 44(5):383–389. https://doi.org/10.1590/ S1806-37562017000000420. PMID:30517339; PMCID: PMC6467596
- 27. Seersholm N (1997) Body mass index and mortality in patients with severe α1-antitrypsin deficiency. Respir Med 91(2):77–82
- de Serres FJ (2002) Worldwide racial and ethnic distribution of α1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 122(5):1818–1829
- Greulich T, Nell C, Hohmann D et al (2017) The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J 49(1):1600154
- Winther SV, Ahmed D, Al-Shuweli S et al (2022) Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis. Respir Res 23(1):55
- Le Boedec K (2016) Sensitivity and specificity of normality tests and consequences on reference interval accuracy at small sample size: a computer-simulation study. Vet Clin Pathol 45(4):648–656

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- ► High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at > springeropen.com